A Novel Mutation (c.200T>C) in the NAGLU Gene of a Korean Patient with Mucopolysaccharidosis IIIB

다국어 초록 (Multilingual Abstract)

Mucopolysaccharidosis (MPS) IIIB is a lysosomal storage disorder (LSD) caused by abnormalities of the enzyme α-N-acetylglucosaminidase (NAGLU) that is required for degradation of heparan sulfate. The patient in this study was a 4-yr-old boy. He presented with normal height and weight, pectus carinatum, and multiple persistent Mongolian spots on his back. He had mild dysmorphic features with prominent speech developmental delays and, to a lesser extent, motor developmental delays. The cetylpyridinium chloride precipitation test revealed excessive mucopolysacchariduria (657.2 mg glycosaminoglycan/g creatinine;reference range, <175 mg glycosaminoglycan/g creatinine). Thin layer chromatography showed urinary heparan sulfate excretion. NAGLU enzyme activity was significantly decreased in leukocytes (not detected; reference range, 0.9-1.51 nmol/hr/mg protein)as well as in plasma (0.14 nmol/hr/mg protein; reference range, 22.3-60.9 nmol/hr/mg protein). PCR and direct sequencing analysis of the NAGLU gene showed that the patient was a compound heterozygote for 2 mutations: c.200T>C (p.L67P) and c.1444C>T (p.R482W). The c.200T>C mutation was a novel finding. This is the first report of a Korean patient with MPS IIIB who was confirmed by molecular genetic analyses and biochemical investigation.

참고문헌 (Reference)

1 Zhao HG, "The molecular basis of Sanfilippo syndrome type B" 93 : 6101-6105, 1996

2 Poorthuis BJ, "The frequency of lysosomal storage diseases in The Netherlands" 105 : 151-156, 1999

3 Weber B, "Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes" 7 : 34-44, 1999

4 Valstar MJ, "Sanfilippo syndrome: A mini-review" 31 : 240-252, 2008

5 Verhoeven WM, "Sanfilippo B in an elderly female psychiatric patient: a rare but relevant diagnosis in presenile dementia" 122 : 162-165, 2010

6 Ng PC, "Predicting deleterious amino acid substitutions" 11 : 863-874, 2001

7 Valstar MJ, "Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype" 33 : 759-767, 2010

8 Bunge S, "Mucopolysaccharidosis type IIIB (Sanfilippo B): identification of 18 novel alpha-N-acetylglucosaminidase gene mutations" 36 : 28-31, 1999

9 Yogalingam G, "Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications" 18 : 264-281, 2001

10 Tanaka A, "Molecular analysis of the alpha-N-acetylglucosaminidase gene in seven Japanese patients from six unrelated families with mucopolysaccharidosis IIIB (Sanfilippo type B), including two novel mutations" 47 : 484-487, 2002

11 Lin HY, "Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004" 149A : 960-964, 2009

12 Héron B, "Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece" 155A : 58-68, 2011

13 Saudubray JM, "Inborn metabolic disease. 5th ed" Springer 580-590, 2012

14 Ramensky V, "Human non-synonymous SNPs: server and survey" 30 : 3894-3900, 2002

15 Zhao HG, "Genotype-phenotype correspondence in Sanfilippo syndrome type B" 62 : 53-63, 1998

16 van de Kamp JJ, "Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C)" 20 : 152-160, 1981

17 Baehner F, "Cumulative incidence rates of the mucopolysaccharidoses in Germany" 28 : 1011-1017, 2005

18 Weber B, "Cloning and expression of the gene involved in Sanfilippo B syndrome (mucopolysaccharidosis III B)" 5 : 771-777, 1996

19 손우연, "Clinical and Laboratory Features of Korean Mucopolysaccharidoses (MPSs)" 대한소아과학회 48 (48): 1132-1138, 2005